logo
Plus   Neg
Share
Email

Bausch Health Plans To Spin Off Eye Health Business

Bausch Health Companies Inc. (BHC,BHC.TO) announced Thursday it intends to spin off its eye health business into an independent publicly traded entity from the remainder of Bausch Health.

In pre-market activity, Bausch Health shares gained 20 percent to trade at $23.32.

The spinoff will establish two separate companies, such as a fully integrated, pure play eye-health company built on the iconic Bausch + Lomb brand, as well as a diversified pharmaceutical company.

The new Bausch + Lomb - NewCo will consist of Bausch Health's global vision care, surgical, consumer and ophthalmic Rx businesses. It would have had 2019 revenue of approximately $3.7 billion.

Further, BHC will comprise a diversified portfolio of durable brands across the Salix, International Rx, Solta, neurology and medical dermatology businesses. It would have had 2019 revenue of approximately $4.9 billion.

The timing of the anticipated spinoff will be tied to certain conditions and approvals, and the Company's completion of several important actions, including the reorganization of the reporting segments, which it expects to begin reporting in the first quarter of 2021.

The transaction is expected to enable BHC to focus on expanding Gastroenterology, Aesthetics/Dermatology, Neurology and International pharmaceuticals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT